Anteris Technologies Global (AVR), an Australian medical device company, saw its stock soar by 5% in after-hours trading on Friday, following the successful pricing of its US initial public offering (IPO).
The company announced late Thursday that it had priced its US IPO at $6.00 per share for 14.8 million shares, raising approximately $88.8 million in gross proceeds. Anteris also granted underwriters a 30-day option to purchase up to an additional 2.2 million shares.
The strong demand for Anteris' IPO shares, which are set to begin trading on the Nasdaq under the ticker "AVR" on Friday, reflects investor confidence in the company's innovative DurAVR transcatheter heart valve technology and its growth prospects in the expanding medical device market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.